Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 460Myeloid 182Lymphoid 82Thoracic 19Plasma cell 18Gastrointestinal 16Classical hematology 14Genitourinary 10Sarcoma 9Head & Neck 9Dermatologic 9CNS 9Breast 9Gynecologic 7Tumor-Agnostic 3Other solid neoplasm 2Endocrine 1

Conditions

Neoplasm Metastasis 3

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Azacitidine × Tumor-Agnostic × Clear all
NCT07404332 2026-05-28

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa

Phase 1 Recruiting
35 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02959437 2025-10-21

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Incyte Corporation

Phase 1/2 Terminated
70 enrolled 14 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
83 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡